Advertisement

ADVERTISEMENT

Videos

ALK
Rapid Refresh
Understanding the Role of ALK in Cancer Pathogenesis
07/23/2024
This animation explains the role of the ALK oncogene in normal cellular functioning and the effect of an abnormal translocation event where ALK fuses to another gene.
This animation explains the role of the ALK oncogene in normal cellular functioning and the effect of an abnormal translocation event where ALK fuses to another gene.
This animation explains the role...
07/23/2024
APP Institute Oncology
20S Proteasome
Rapid Refresh
Understanding the Role of 20S Proteasome in Cancer Pathogenesis
07/23/2024
This animation explains the role of the 20S proteasome in regulating the cellular life cycle and the effects of disruptions in the ubiquitin proteasome system.
This animation explains the role of the 20S proteasome in regulating the cellular life cycle and the effects of disruptions in the ubiquitin proteasome system.
This animation explains the role...
07/23/2024
APP Institute Oncology
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Paolo Ascierto, MD
Conference Coverage
Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma
07/22/2024
Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.
Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.
Paolo Ascierto, MD, discusses...
07/22/2024
Oncology
Kim Orleck, Kim Kearns
Video
Cochairs Preview First APP Institute Inflammatory Bowel Disease
07/22/2024
Kimberly Orleck and Kim Kearns, APP Institute Inflammatory Bowel Disease cochairs, provide a quick preview of the exciting agenda for the inaugural two-day virtual event.
Kimberly Orleck and Kim Kearns, APP Institute Inflammatory Bowel Disease cochairs, provide a quick preview of the exciting agenda for the inaugural two-day virtual event.
Kimberly Orleck and Kim Kearns,...
07/22/2024
APP Institute Inflammatory Bowel Disease
Paolo Ascierto, MD
Conference Coverage
Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma
07/19/2024
Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.
Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.
Paolo Ascierto, MD, discusses...
07/19/2024
Oncology
David Spigel, MD
Conference Coverage
Durvalumab as Standard-of-Care Consolidation Treatment for Patients With Limited-Stage Small-Cell Lung Cancer
07/19/2024
David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
David Spigel, MD, discusses the...
07/19/2024
Oncology
Jessica Allegretti
Video
Jessica Allegretti, MD, on Recent Advances in Anti-Interleukin Therapies
07/19/2024
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis,
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis,
Dr Allegretti provides key...
07/19/2024
Advances in Inflammatory Bowel Disease Network
Preview Image
Sponsored Video
The WHS WOUNDSHARK 2024 INNOVATION AWARD: Therapeutic BREAKTHROUGH — Eluciderm’s SuperHealer™️ Journey
07/18/2024
Eluciderm, Inc. won the WHS WOUNDSHARK 2024 INNOVATION AWARD at the 2024 International Symposium for Advanced Wound Care (SAWC 2024) as recognition for the anticipated market impact of its groundbreaking ELU42, a first-of-its-kind, topically...
Eluciderm, Inc. won the WHS WOUNDSHARK 2024 INNOVATION AWARD at the 2024 International Symposium for Advanced Wound Care (SAWC 2024) as recognition for the anticipated market impact of its groundbreaking ELU42, a first-of-its-kind, topically...
Eluciderm, Inc. won the WHS...
07/18/2024
Wound Care

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use